Maynard Um
-
-
-
-
-
-
-
Repligen (RGEN) PT Raised to $160 at Wolfe Research
-
-
-
-
-
-
-
RBC Capital Assumes Repligen (RGEN) at Outperform
-
-
-
-
-
-
-
Repligen (RGEN) Tops Q4 EPS by 5c; offers guidance
-
-
-
-
-
-
-
Repligen (RGEN) PT Raised to $160 at Jefferies
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Repligen (RGEN)
-
-
-
-
-
-
-
Maravai LifeSciences (MRVI) on watch on vague chatter following CEO change
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on Repligen (RGEN)
-
466,314 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


